Takeda Receives Clearance from the FTC for the Proposed Acquisition of Shire

Source: Takeda Pharmaceutical

Takeda Pharmaceutical announced that it has received unconditional clearance from the United States Federal Trade Commission (FTC) for the proposed acquisition of Shire announced on May 8, 2018. Takeda’s proposed acquisition of Shire is valued at around 46 billion pounds ($60.9 billion).

The acquisition remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies.

Related Content